Viking Therapeutics, Inc.

Hiroko Masamune

Brian Lian

Geoffrey E Barker

Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

Crystalline forms and methods of producing crystalline forms of a compound

The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

Compositions for the treatment of fibrosis and inflammation

The present disclosure is directed to methods of treating fibrotic conditions by administration of TR&#x3b2; agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TR&#x3b2; agonists with TGF-&#x3b2;-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

Growing community of inventors

San Diego, CA, United States of America

Hiroko Masamune